Indy Hematology Review 2025: State of the Art 2025 - Emerging Therap…

Indy Hematology Review 2025

R. Birhiray

ASH 2025 Review: Updates in Frontline & R/R DLBCL

University of Colorado Division of Hematology

M. Kamdar

Indy Hematology Review 2025: Current Advances in the Treatment of Ag…

Indy Hematology Review 2025

S. Smith

2024 Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

Indy Hematology Review 2025: Current State of Bispecific Antibodies …

Indy Hematology Review 2025

T. Phillips

ASH 2024 Review: Key Updates in Non-Hodgkin Lymphoma

Cleveland Clinic Taussig Cancer Institute

P. Caimi

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

Treating Patients With DLBCL Who Are Not Eligible for CAR-T Therapy

Remy Dulery

Sequencing Cellular Therapy and Bispecific Antibodies in DLBCL

Megan Melody

2025 Updates in DLBCL

Total Health

F. Hagemeister

Indy Hematology Review 2025: Experts Address Key Questions in Hemato…

Indy Hematology Review 2025

R. Stone, M. Lunning, M. Wang, S. Smith, S. Ansell, J. Woyach, J. Byrd, J. Cook

ASH 2024 Insights: Outcomes With Bispecific Antibodies Post-CAR T-Ce…

2024 ASH Annual Meeting Insights Hub

M. Melody

Tafasitamab + Lenalidomide in R/R DLBCL: Updated Results From the L-…

David Bond

Updates on Approved CAR-Ts for Lymphomas

Moffitt Cancer Center

J. Chavez

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

Indy Hematology Review 2025: Updates in Cellular Therapy for DLBCL a…

Indy Hematology Review 2025

M. Lunning

ASH 2024 Insights: Timing of CAR-T Failure as a Predictor of Outcome…

2024 ASH Annual Meeting Insights Hub

E. Shumilov

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

Managing R/R LBCL Patients Treated With Pola-R-CHP in 1L and Are CAR…

University of Colorado Cancer Center

M. Kamdar

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde